{
 "awd_id": "9060227",
 "agcy_id": "NSF",
 "tran_type": "Grant",
 "awd_istr_txt": "Standard Grant",
 "awd_titl_txt": "Genetic Engineering of a Ricin Immunotoxin",
 "cfda_num": "47.084",
 "org_code": "15030000",
 "po_phone": null,
 "po_email": "",
 "po_sign_block_name": "Ritchie B. Coryell",
 "awd_eff_date": "1991-01-01",
 "awd_exp_date": "1991-09-30",
 "tot_intn_awd_amt": 50000.0,
 "awd_amount": 50000.0,
 "awd_min_amd_letter_date": "1990-12-14",
 "awd_max_amd_letter_date": "1990-12-14",
 "awd_abstract_narration": "The construction and expression of a recombinant immunotoxin                    consisting of a single chain antibody fused to ricin toxin is                   proposed.  The use of recombinant DNA technology to design and                  express immunotoxins has numerous advantages over current                       biochemical methods of preparation.  These include formation of a               recombinant protein that contains only the sequences required for               specific cell recognition and cytotoxic activity.  Prokaryotic                  expression systems an provide high yields of uniformly produced                 protein.  Intact ricin contains nonspecific galactose-binding                   sites, currently these must be blocked y chemical means in order                to permit the antibody portion of the immunotoxin to selectively                target tumors.  Expression of recombinant ricin in E.coli will                  facilitate the mutagenesis and screening of genetically modified                lectin-deficient ricin immunotoxins.  If biologically active, a                 recombinant ricin immunotoxin will permit dissection of the nature              of ricin binding and entry into cells, and will serve as a                      prototype in the molecular restructuring of other carrier                       protein/ricin hybrids.",
 "awd_arra_amount": 0.0,
 "dir_abbr": "TIP",
 "org_dir_long_name": "Directorate for Technology, Innovation, and Partnerships",
 "div_abbr": "TI",
 "org_div_long_name": "Translational Impacts",
 "awd_agcy_code": "4900",
 "fund_agcy_code": "4900",
 "pi": [
  {
   "pi_role": "Principal Investigator",
   "pi_first_name": "Braydon",
   "pi_last_name": "Guild",
   "pi_mid_init": "C",
   "pi_sufx_name": "",
   "pi_full_name": "Braydon C Guild",
   "pi_email_addr": "",
   "nsf_id": "000090692",
   "pi_start_date": "1991-01-01",
   "pi_end_date": null
  }
 ],
 "inst": {
  "inst_name": "ImmunoGen Incorporated",
  "inst_street_address": "148 Sidney St",
  "inst_street_address_2": "",
  "inst_city_name": "Cambridge",
  "inst_state_code": "MA",
  "inst_state_name": "Massachusetts",
  "inst_phone_num": "6176619312",
  "inst_zip_code": "021394239",
  "inst_country_name": "United States",
  "cong_dist_code": "07",
  "st_cong_dist_code": "MA07",
  "org_lgl_bus_name": null,
  "org_prnt_uei_num": null,
  "org_uei_num": null
 },
 "perf_inst": {
  "perf_inst_name": "DATA NOT AVAILABLE",
  "perf_str_addr": "",
  "perf_city_name": "",
  "perf_st_code": "",
  "perf_st_name": "RI REQUIRED",
  "perf_zip_code": "",
  "perf_ctry_code": "",
  "perf_cong_dist": "",
  "perf_st_cong_dist": "",
  "perf_ctry_name": "",
  "perf_ctry_flag": "0"
 },
 "pgm_ele": [
  {
   "pgm_ele_code": "537100",
   "pgm_ele_name": "SBIR Phase I"
  }
 ],
 "pgm_ref": [
  {
   "pgm_ref_code": "1112",
   "pgm_ref_txt": "GENES AND GENOME SYSTEMS"
  },
  {
   "pgm_ref_code": "5371",
   "pgm_ref_txt": "SMALL BUSINESS PHASE I"
  }
 ],
 "app_fund": [
  {
   "app_code": "",
   "app_name": "",
   "app_symb_id": "",
   "fund_code": "",
   "fund_name": "",
   "fund_symb_id": ""
  }
 ],
 "oblg_fy": [
  {
   "fund_oblg_fiscal_yr": 1991,
   "fund_oblg_amt": 50000.0
  }
 ],
 "por": null
}